BR112015030591A2 - formas de polimorfos de maleato de icotinib e usos dos mesmos - Google Patents

formas de polimorfos de maleato de icotinib e usos dos mesmos

Info

Publication number
BR112015030591A2
BR112015030591A2 BR112015030591A BR112015030591A BR112015030591A2 BR 112015030591 A2 BR112015030591 A2 BR 112015030591A2 BR 112015030591 A BR112015030591 A BR 112015030591A BR 112015030591 A BR112015030591 A BR 112015030591A BR 112015030591 A2 BR112015030591 A2 BR 112015030591A2
Authority
BR
Brazil
Prior art keywords
polymorph forms
icotinib maleate
maleate polymorph
icotinib
forms
Prior art date
Application number
BR112015030591A
Other languages
English (en)
Other versions
BR112015030591B1 (pt
Inventor
Wang Fei
Ding Lieming
Hu Shaojing
Long Wei
Wang Yinxiang
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of BR112015030591A2 publication Critical patent/BR112015030591A2/pt
Publication of BR112015030591B1 publication Critical patent/BR112015030591B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

resumo patente de invenção: "formas de polimorfos de maleato de icotinib e usos dos mesmos". a presente invenção se refere-se a maleato de icotinib (o composto de fórmula i) e formas de polimorfos do mesmo, e métodos de preparação e uso deles. fórmula i
BR112015030591-1A 2013-06-09 2014-06-09 Formas de polimorfos de maleato de icotinib, processo de preparação das referidas formas, composição farmacêutica e usos das mesmas BR112015030591B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013077093 2013-06-09
CNPCT/CN2013/077093 2013-06-09
PCT/CN2014/079484 WO2014198210A1 (en) 2013-06-09 2014-06-09 Polymorph forms of icotinib maleate and uses thereof

Publications (2)

Publication Number Publication Date
BR112015030591A2 true BR112015030591A2 (pt) 2017-07-25
BR112015030591B1 BR112015030591B1 (pt) 2022-09-13

Family

ID=52021656

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030591-1A BR112015030591B1 (pt) 2013-06-09 2014-06-09 Formas de polimorfos de maleato de icotinib, processo de preparação das referidas formas, composição farmacêutica e usos das mesmas

Country Status (12)

Country Link
US (1) US9505774B2 (pt)
EP (1) EP3008070B9 (pt)
JP (1) JP6518655B2 (pt)
KR (1) KR102263410B1 (pt)
AU (1) AU2014280709B2 (pt)
BR (1) BR112015030591B1 (pt)
CA (1) CA2914854C (pt)
ES (1) ES2656699T3 (pt)
RU (1) RU2708079C9 (pt)
SG (1) SG11201509750VA (pt)
TW (1) TWI596098B (pt)
WO (1) WO2014198210A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
WO2010003313A1 (zh) 2008-07-08 2010-01-14 浙江贝达药业有限公司 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途
AU2012331547C1 (en) 2011-10-31 2016-04-21 Betta Pharmaceuticals Co., Ltd Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof

Also Published As

Publication number Publication date
EP3008070A4 (en) 2016-08-10
AU2014280709A1 (en) 2016-01-21
JP2016520624A (ja) 2016-07-14
CA2914854C (en) 2017-08-22
RU2016100026A (ru) 2017-07-20
EP3008070B9 (en) 2018-05-23
KR102263410B1 (ko) 2021-06-10
US20160137658A1 (en) 2016-05-19
RU2708079C9 (ru) 2020-02-28
US9505774B2 (en) 2016-11-29
ES2656699T3 (es) 2018-02-28
CA2914854A1 (en) 2014-12-18
KR20160018711A (ko) 2016-02-17
BR112015030591B1 (pt) 2022-09-13
WO2014198210A1 (en) 2014-12-18
EP3008070B1 (en) 2017-11-15
ES2656699T9 (es) 2018-06-04
RU2708079C2 (ru) 2019-12-04
TW201512203A (zh) 2015-04-01
EP3008070A1 (en) 2016-04-20
AU2014280709B2 (en) 2017-05-04
SG11201509750VA (en) 2015-12-30
TWI596098B (zh) 2017-08-21
JP6518655B2 (ja) 2019-05-22

Similar Documents

Publication Publication Date Title
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA201590534A1 (ru) Новые бициклические производные
EA201501142A1 (ru) Гетероциклические соединения в качестве средств для борьбы с вредителями
BR112015000561A2 (pt) inibidores de irak e usos dos mesmos
UA113062C2 (xx) Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону
EA201591064A1 (ru) Новые производные пиридина
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201690478A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТРИАЗОЛ[4,5-d]ПИРИМИДИНА
EA201591624A1 (ru) Новые производные пиразола
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
EA201691141A1 (ru) Соединения против ccr6
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
EA201500931A1 (ru) Производные пиридин-4-ила
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
EA201590475A1 (ru) Тетрациклиновые соединения
EA201591939A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРА CB2
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
BR112017004000A2 (pt) formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/06/2014, OBSERVADAS AS CONDICOES LEGAIS